UNLOCKING

CARDIOLOGY

IMMUNOLOGY

HEaLTHCARE

Life

We aim to create a lasting and meaningful impact on patients suffering from cardiac conditions.

Cardiovascular diseases are a major burden and the first cause of death globally.

18₊

Millions
deaths/year

85_%

caused by myocardial infarction
& stroke

300

millions Disability-adjusted
life years (DALY)

We unlock the potential of immunotherapies to reshape the future of Cardiovascular care.
The momentum around emerging Cardio-immunology field has never been stronger.

Our revolution

Patients

We aim to drastically reduce the burden of cardiovascular diseases by providing preventing treatments to patients, thereby decreasing the risk of cardiovascular events

Technology

We designed a first in class monoclonal antibody that specifically targets the immune system to prevent cardiac damage in ischemic cardiovascular diseases.

about POLYGON

Polygon emerges from cutting-edge academic research. The project is led by three co-founders with complementary backgrounds, all geared up to bring innovation from bench to patients' bed in a fresh, bold and committed approach.

NEWS

Our Latest news

Prof Hafid Ait-Oufella appointed member of the Collège of French National Academy of Medicine

January 19, 2026

New publication in Cardiovascular Research journal: Targeting CD8+ T Cells in Cardiovascular Diseases

June 4, 2025

Polygon at the J.P. Morgan Healthcare Conference Week 2025

January 13, 2025